Xcell Biosciences Strengthens Cell and Gene Therapy Collaboration With Labcorp - Seite 2
Through the expanded collaboration, Labcorp’s preclinical oncology site in Ann Arbor, Mich., will become a beta site for the AVATAR Foundry system. More information about the beta access program is available at https://www.xcellbio.com/gmp.
“We are proud to be a trusted partner for Labcorp, who recognizes that key partnerships will help unlock what’s possible in the development of cell and gene therapies,” said Brian Feth, co-founder and CEO at Xcellbio. “We look forward to deepening our ties as we continue on our shared mission of developing safer, more effective treatments for more patients and a wide array of diseases.”
Poster Presentations at AACR
Along with scientific collaborators at Labcorp, Xcell team members will be presenting two posters at the upcoming AACR annual meeting, taking place April 5-10 in San Diego.
Poster #3908: Generation of new oncology cell models through long-term acclimation under hypoxic and hyperbaric culture conditions
Presenter: Yewei Xing, Labcorp
Summary: In this poster, scientists will show that long-term acclimation of conventional tumor cell lines to conditions reflective of the TME alters their phenotype and gene expression profiles.
Poster #6334: Metabolic reprogramming enhances expansion and potency of CAR-T cells
Presenter: Candy Garcia and James Lim, Xcellbio
Summary: This presentation will illustrate how manufacturing CD19 CAR T cells in optimized environmental conditions can enhance their expansion potential and potency, as measured with an in
vitro tumor killing assay.
About Xcell Biosciences
Lesen Sie auch
Xcellbio is driven by its mission to enhance the performance and safety of cell and gene-based therapies through the design and development of revolutionary technology platforms. The company’s commercial instruments and AI-driven software allow researchers to discover novel insights into immune and tumor biology and enable the translation of these insights at patient scale through the development of its pioneering cGMP cell therapy manufacturing platform. Based in San Francisco, Xcellbio can also be found online at www.xcellbio.com.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in over 100 countries, worked on over 84% of the new drugs approved by the FDA in 2023 and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401023455/en/
The Laboratory Of America Holdings Stock at the time of publication of the news with a raise of +2,00 % to 204USD on Tradegate stock exchange (28. März 2024, 22:02 Uhr).